-
EP2678013
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2678013
| EP2678013 - COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH RADIOTHERAPY [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 03.06.2016 Database last updated on 15.06.2024 | Most recent event Tooltip | 03.06.2016 | Application deemed to be withdrawn | published on 06.07.2016 [2016/27] | Applicant(s) | For all designated states Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 / US | [2014/01] | Inventor(s) | 01 /
FOLEY, Kevin, P. 4402 Merchant Square Place Landsdale, PA 19446 / US | 02 /
PROIA, David 30 Silver Lake Avenue Newton, MA 02458 / US | [2014/01] | Representative(s) | Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB | [N/P] |
| Former [2014/01] | Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham NG1 5GG / GB | Application number, filing date | 12707012.6 | 22.02.2012 | WO2012US26101 | Priority number, date | US201161445589P | 23.02.2011 Original published format: US 201161445589 P | [2014/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2012116061 | Date: | 30.08.2012 | Language: | EN | [2012/35] | Type: | A1 Application with search report | No.: | EP2678013 | Date: | 01.01.2014 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.08.2012 takes the place of the publication of the European patent application. | [2014/01] | Search report(s) | International search report - published on: | EP | 30.08.2012 | Classification | IPC: | A61K31/4196, A61P35/00 | [2014/01] | CPC: |
A61K31/675 (EP,US);
A61K31/4196 (EP,US);
A61K45/06 (EP,US);
A61P35/00 (EP);
A61N2005/1098 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/01] | Extension states | BA | 20.09.2013 | ME | 20.09.2013 | Title | German: | KOMBINATIONSTHERAPIE AUS HSP90-HEMMENDEN VERBINDUNGEN UND STRAHLENTHERAPIE | [2014/01] | English: | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH RADIOTHERAPY | [2014/01] | French: | POLYTHÉRAPIE ASSOCIANT DES COMPOSÉS INHIBITEURS DE HSP90 À UNE RADIOTHÉRAPIE | [2014/01] | Entry into regional phase | 20.09.2013 | National basic fee paid | 20.09.2013 | Designation fee(s) paid | 20.09.2013 | Examination fee paid | Examination procedure | 20.09.2013 | Examination requested [2014/01] | 17.04.2014 | Amendment by applicant (claims and/or description) | 15.09.2014 | Despatch of a communication from the examining division (Time limit: M06) | 23.03.2015 | Reply to a communication from the examining division | 25.09.2015 | Despatch of a communication from the examining division (Time limit: M04) | 06.02.2016 | Application deemed to be withdrawn, date of legal effect [2016/27] | 01.03.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2016/27] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 15.09.2014 | Fees paid | Renewal fee | 27.02.2014 | Renewal fee patent year 03 | 26.02.2015 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 29.02.2016 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XP]WO2011149824 (SYNTA PHARMACEUTICALS CORP [US], et al) [XP] 1-23 * See the claimed compounds and see pages 15 last paragraph and page 41 last but one paragraph: combination with radiotherapy *; | [XP]WO2011133520 (SYNTA PHARMACEUTICALS CORP [US], et al) [XP] 1-23 * See the claimed compounds and see page 39 second full paragraph: combination with radiotherapy *; | [XP]WO2011133521 (SYNTA PHARMACEUTICALS CORP [US], et al) [XP] 1-23 * See claimed compounds and see page 37 las paragraph: combinations with radiotherapy *; | [Y]WO2006055760 (SYNTA PHARMACEUTICALS CORP [US], et al) [Y] 1-23 * See claim 1, 47 (3rd compound), claims 52-54, the claimed compounds, as HSP-90 inhibitors, alone or in combination with other therapies (page 125), for use in the treatment of cancer *; | [Y]WO2009023211 (SYNTA PHARMACEUTICALS CORP [US], et al) [Y] 1-23 * See the HSP-90 inhibitors disclosed in claims 1, 53, 67, 80, 86, and in claim 91 (third compound) and in examples 1-3 at pages 126 ff, and see the examples A-L and figures, their use to inhibit HSP-90 and to treat cancer, alone or in combination with other therapies (see page 97) *; | [Y]EP2133094 (KYOWA HAKKO KIRIN CO LTD [JP]) [Y] 1-23 * See claims and paragraph [0062]: combination of HSP inhibitors and radiation therapy * | [Y] - ALEXANDER E KABAKOV ET AL, "Hsp90 inhibitors as promising agents for radiotherapy", JOURNAL OF MOLECULAR MEDICINE, SPRINGER, BERLIN, DE, (20091128), vol. 88, no. 3, ISSN 1432-1440, pages 241 - 247, XP019791487 [Y] 1-23 * See abstract: HSP-90 inhibitors sensitize human tumors to irradiation and improve the outcome of radiotherapy. See in particular figure 2, compound BIIB021 and see table 1 * | [Y] - NOGUCHI M ET AL, "Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygelda namycin", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 351, no. 3, doi:10.1016/J.BBRC.2006.10.094, ISSN 0006-291X, (20061222), pages 658 - 663, (20061222), XP024925735 [Y] 1-23 * See abstract and conclusion: the HSP90 inhibitor 17-AAG sensitizes cells to irradiation damage * DOI: http://dx.doi.org/10.1016/j.bbrc.2006.10.094 | by applicant | US2006167070 | WO2009023211 | US3845770 | US3916899 | US3536809 | US3598123 | US4008719 | US5674533 | US5059595 | US5591767 | US5120548 | US5073543 | US5639476 | US5354556 | US5733566 | - STINGL ET AL., "Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.", BR J CANCER., vol. 102, no. 11, pages 1578 - 1591 |